CAR-T Pipeline Update: Celgene posts pivotal data ahead of FDA filing

Celgene has recently published positive data from a pivotal trial (NCT02631044) of its CAR-T therapy. As per the reports, the data look competitive against Gilead’s Yescarta and Novartis’ Kymriah, leading analysts to predict Celgene will win FDA approval next year. This is a big news for the overall CAR-T pipeline.

As per the reported data, the response rates are around 20 percentage points higher than those on the Kymriah label and one or two percentage points above the results achieved by Yescarta. As the three drugs were studied in different trials, factors other than their efficacy may account for the differences.

For more, check out the coverage here.

How many approved CAR-T therapies are available: We currently have 2 approved products, namely KYMRIAH® (Novartis) and YESCARTA® (Gilead Sciences).

How many CAR-T therapies are in development: There are currently more than 530+ CAR-T therapies in development. Below is the distribution of the CAR-T pipeline by the phase of development:

To get more insights about the CAR-T pipeline, check out the detailed report Car_T Therapy Market 2nd Edition.